Multiple-Dose Dose-Escalation Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
This study is being done to help answer the following research questions about the potential new drug, LY3303560, for the treatment of AD: Is LY3303560 safe and what is the best dose? Are there side effects experienced when taking LY3303560? What the body does to LY3303560?
How does LY3303560 affect certain proteins in the brain of people with AD?
Description
The purpose of this study is to evaluate the effects of repeated monthly administrations in patients with mild cognitive impairment (MCI) due to AD or mild to moderate AD over approximately 12 months.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 50 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1706842397
